發(fā)布時(shí)間：2018-06-26 22:40

  本文選題：非霍奇金淋巴瘤 + 白細(xì)胞介素21��； 參考：《遵義醫(yī)學(xué)院》2017年碩士論文

【摘要】：目的:檢測(cè)非霍奇金淋巴瘤(NHL)患者血清中白細(xì)胞介素21(IL-21)的表達(dá)水平,探索IL-21與NHL的發(fā)病及預(yù)后的相關(guān)性。方法:選擇2015年12月至2016年12月遵義醫(yī)學(xué)院附屬醫(yī)院收治的36例NHL患者作為研究對(duì)象(初診NHL患者20例,化療后NHL患者16例),13例健康體檢者作為正常對(duì)照組,應(yīng)用酶聯(lián)免疫吸附試驗(yàn)(ELISA)測(cè)定NHL患者及對(duì)照組血清IL-21水平,對(duì)比初診NHL患者血清IL-21水平在年齡、性別、分期、分組、有無(wú)結(jié)外浸潤(rùn)等臨床因素的差別,分析治療前后NHL患者血清IL-21水平的變化,探討血清IL-21水平在NHL患者中表達(dá)及臨床意義。結(jié)果:1)NHL患者血清IL-21水平(200.75±58.91ng/L)明顯低于對(duì)照組(420.91±132.56ng/L),差異具有統(tǒng)計(jì)學(xué)意義(P0.05);2)初診NHL處于III期和IV期患者血清IL-21水平(153.77±25.97ng/L)顯著低于I期和II期患者血清IL-21水平(223.87±35.36ng/L),差異具有統(tǒng)計(jì)學(xué)意義(P0.05);初診NHL患者中有全身癥狀者血清IL-21水平(141.15±17.95ng/L)低于無(wú)全身癥狀者血清IL-21水平(208.46±33.50ng/L),差異具有統(tǒng)計(jì)學(xué)意義(P0.05);初診NHL患者中有結(jié)外浸潤(rùn)者血清IL-21水平(143.94±19.38ng/L)明顯低于無(wú)結(jié)外浸潤(rùn)者血清IL-21水平(212.53±32.80ng/L),差異具有統(tǒng)計(jì)學(xué)意義(P0.05);初診NHL患者中60歲者血清IL-21水平(168.13±52.02ng/L)與≤60歲者血清IL-21水平(177.03±41.86ng/L)無(wú)明顯差異(P0.05);初診NHL中男性患者血清IL-21水平(186.99±41.09ng/L)與女性患者血清IL-21水平(156.52±42.47ng/L)無(wú)明顯差異(P0.05);初診B細(xì)胞型NHL患者血清IL-21水平(176.70±40.46ng/L)與初診T細(xì)胞型NHL患者血清IL-21水平(167.21±60.02ng/L)無(wú)明顯差異(P0.05);3)20例初診NHL患者中有12例經(jīng)治療后取得緩解或部分緩解,治療前患者血清IL-21水平為(162.63±38.75ng/L),治療緩解后患者血清IL-21水平為(264.45±43.89ng/L),治療前、治療緩解后NHL患者血清IL-21水平比較差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:1)IL-21表達(dá)水平下調(diào)可能與NHL的發(fā)病有一定相關(guān)性;2)IL-21表達(dá)水平與NHL的分期、分組及有無(wú)結(jié)外浸潤(rùn)有關(guān),治療緩解后患者血清IL-21水平明顯高于治療前患者,提示IL-21的表達(dá)水平可能與NHL的預(yù)后有關(guān)。
[Abstract]:Aim: to detect the expression of interleukin-21 (IL-21) in serum of patients with non Hodgkin's lymphoma (NHL) and to explore the correlation between IL-21 and the pathogenesis and prognosis of NHL. Methods: from December 2015 to December 2016, 36 NHL patients treated in affiliated Hospital of Zunyi Medical College were selected as study subjects (20 newly diagnosed NHL patients and 16 NHL patients after chemotherapy) and 13 healthy persons as normal control group. The serum levels of IL-21 in NHL patients and controls were measured by enzyme linked immunosorbent assay (Elisa). To analyze the changes of serum IL-21 levels in NHL patients before and after treatment, and to explore the expression and clinical significance of serum IL-21 levels in NHL patients. Results the level of IL-21 in NHL patients (200.75 鹵58.91ng / L) was significantly lower than that in controls (420.91 鹵132.56ng / L), the difference was statistically significant (P0.05). The level of IL-21 in patients with stage III and stage IV was significantly lower than that in patients with stage I and II (223.87 鹵35.36ngL). The level of serum IL-21 in patients with systemic symptoms (141.15 鹵17.95 ng / L) was significantly lower than that in patients without systemic symptoms (208.46 鹵33.50 ng / L) (P0.05), and the level of IL-21 in patients with extranodular infiltration (143.94 鹵19.38 ng / L) was significantly lower than that in patients without nodule (P 0.05). There was no significant difference in serum IL-21 level (212.53 鹵32.80ng / L) between the first diagnosed NHL patients (168.13 鹵52.02ng / L) and those 鈮，

本文編號(hào)：2071666